Science Advances, has published a research article describing our proteomics technology AbiProt®, a high-tech antibody discovery approach with the potential to bring several novel antibody medicines to large patient populations in multiple disease areas.

 

We are very happy and proud to announce that the highly esteemed scientific journal Science Advances has published a research article describing how we discovered and developed two antibodies targeting TRPV1 (moduli-selective antagonist for pain) and KRAS (mutant-selective antagonist for cancer), respectively. These are two clinically highly important targets that were previously considered undruggable with antibodies. We did it with AbiProt, our in-house developed high-tech/proteomics technology that we believe has the potential to bring several novel antibody medicines to large patient populations in multiple disease areas.

 

You can have a copy of your manuscript at http://advances.sciencemag.org/

Science Advances  16 Apr 2021: Vol. 7, no. 16, eabe6397 DOI: 10.1126/sciadv.abe6397

 

You can read our Press Release clicking here:

English Version: Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to bring several novel antibody medicines to large patient populations in multiple disease areas

Swedish Version: Science Advances publicerar artikel om proteomikteknik från Oblique Therapeutics AB som kan bidra till utveckling av nya antikroppsläkemedel till stora patientpopulationer inom flera sjukdomsområden